corporate governance careers our science pipeline & productrapivab next generation kallikrein inhibitors for hae bcx4430 investorsanalyst coverage events & presentations email alerts financial profile investors faq information request news proxy online sec documents stock information contact ir news & resourceslatest news hae publications bcx4430 publications biocryst pharmaceuticals inc. biocryst pharmaceuticals designs optimizes and develops novel small molecule drugs that block key enzymes to treat rare diseases . rapivab fda approved december 2014 rapivab licensed to csl now seqirus for the treatment of influenza june 2015 learn more to learn more about biocryst pharmaceuticals please read the company s 2015 10k annual report and 2016 proxy . read our annual report read our proxy biocryst s core development programs include bcx7353 and other 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema and bcx4430 a broad spectrum antiviral for hemorrhagic fevers . learn more about biocryst s broad spectrum antiviral bcx4430 galidesivir a potential medical countermeasure for filoviruses . latest newsseptember 26 2016biocryst closes 23 million senior credit facility september 7 2016biocryst announces positive study results for bcx4430 delayed treatment of ebola virus infection in a non human primate modelaugust 31 2016biocryst to present at the baird 2016 global healthcare conference september 8view allrecent event r.w. baird conference sept 8th connect to webcast 2016 biocryst pharmaceuticals inc. all rights reserved . disclaimer